Early Management of Non-ST-Elevation Acute Coronary Syndrome
All patients with NSTE-ACS (NSTEMI or unstable angina) should immediately receive dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) and anticoagulation, with fibrinolytic therapy absolutely contraindicated in this population 1.
Immediate Antiplatelet Therapy
Aspirin
- Loading dose: 162-325 mg (chewed for faster absorption)
- Maintenance: 81 mg daily (especially if using ticagrelor) 1
- Continue indefinitely 1
P2Y12 Inhibitor Selection
The choice follows this hierarchy based on 2014 AHA/ACC guidelines 1:
Preferred agents (in order):
- Ticagrelor: 180 mg loading dose, then 90 mg twice daily (reasonable to prefer over clopidogrel) 1
- Prasugrel: 60 mg loading dose, then 10 mg daily (if undergoing PCI and not high bleeding risk) 1
- Clopidogrel: 300-600 mg loading dose, then 75 mg daily (if above agents unavailable or contraindicated)
Continue P2Y12 inhibitor for 12 months regardless of revascularization strategy 1
Immediate Anticoagulation
Choose ONE of the following (all Class I recommendations) 1:
- Enoxaparin: 1 mg/kg subcutaneous every 12 hours (reduce to once daily if CrCl <30 mL/min) - Level of Evidence A
- Fondaparinux: 2.5 mg subcutaneous daily - Level of Evidence B
- Critical caveat: Must add UFH or bivalirudin during PCI to prevent catheter thrombosis 1
- Bivalirudin: 0.10 mg/kg bolus, then 0.25 mg/kg/hour (only for early invasive strategy) - Level of Evidence B
- Unfractionated heparin: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/hour (max 1000 IU/h) adjusted to aPTT - Level of Evidence B
Critical Contraindication
Intravenous fibrinolytic therapy is contraindicated and causes harm in NSTE-ACS (Class III: Harm, Level of Evidence A) 1. This distinguishes NSTE-ACS management fundamentally from STEMI.
Additional Acute Therapies
Anti-Ischemic Medications
- Nitroglycerin: Sublingual or IV for ongoing chest pain (avoid if hypotensive, right ventricular infarction, or recent phosphodiesterase inhibitor use)
- Beta-blockers: Oral within 24 hours if no contraindications (heart failure, hypotension, bradycardia, heart block)
- High-intensity statin: Initiate immediately (atorvastatin 80 mg or rosuvastatin 40 mg)
Glycoprotein IIb/IIIa Inhibitors
May be considered (Class IIb) in intermediate/high-risk patients (positive troponin) undergoing early invasive strategy, with eptifibatide or tirofiban preferred 1. This represents a downgrade from routine use, reflecting more selective application.
Risk Stratification for Invasive Strategy Timing
The 2020 ESC guidelines 2 and 2014 AHA/ACC guidelines 1 align on timing:
Immediate invasive strategy (<2 hours) for very high-risk features:
- Hemodynamic instability or cardiogenic shock
- Recurrent/refractory chest pain despite medical therapy
- Life-threatening arrhythmias or cardiac arrest
- Mechanical complications
- Acute heart failure
- Recurrent dynamic ST-segment or T-wave changes
Early invasive strategy (within 24 hours) for high-risk features:
- Elevated troponin
- Dynamic ST-segment or T-wave changes
- GRACE score >140
- Diabetes mellitus
Common Pitfalls to Avoid
- Never administer fibrinolytics - this is the single most important distinction from STEMI management and causes harm 1
- Don't forget additional anticoagulation with fondaparinux at PCI - catheter thrombosis risk is real 1
- Aspirin dose matters with ticagrelor - use 81 mg maintenance, not higher doses 1
- Don't delay antiplatelet/anticoagulation while awaiting catheterization - start immediately upon diagnosis 1
The evidence strongly supports this aggressive early medical management even before defining coronary anatomy, as it reduces mortality and recurrent ischemic events in this population that comprises approximately 70% of all ACS presentations 3.